| Dr William A Wilmer, MD | |
|
595 Copeland Mill Rd, Suite 2d, Westerville, OH 43081-8908 | |
| (614) 823-8500 | |
| (614) 823-8501 |
| Full Name | Dr William A Wilmer |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 36 Years |
| Location | 595 Copeland Mill Rd, Westerville, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750380481 | NPI | - | NPPES |
| 0816264 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 35060681 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fmc Canal Winchester, Llc | Pickerington, OH | Dialysis facility |
| Fmc - Hocking Hills Dialysis Center | Lancaster, OH | Dialysis facility |
| Davita - Logan Dialysis | Logan, OH | Dialysis facility |
| Fairfield Medical Center | Lancaster, OH | Hospital |
| Mount Carmel East & West | Columbus, OH | Hospital |
| Mount Carmel St Ann's | Westerville, OH | Hospital |
| Hocking Valley Community Hospital | Logan, OH | Hospital |
| Riverside Methodist Hospital | Columbus, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kidney Specialists, Inc. | 7719871474 | 8 |
News Archive
Gensignia scientific co-founders' research has been recognized in Clinical Cancer Advances 2015: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology published online in the Journal of Clinical Oncology (JCO) on January 20, 2015.
While several COVID-19 vaccines have been approved to date, the constant evolution of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) receptor-binding domain (RBD) has challenged the efficacy of these vaccines.
Palomar Medical Technologies Inc., a leading researcher and developer of light-based systems for cosmetic treatments, today announced the termination of its agreement with Johnson & Johnson Consumer Companies Inc ("JJCC"), a Johnson & Johnson company, to develop, clinically test and commercialize home-use, light-based devices for (i) reducing or reshaping body fat including cellulite; (ii) reducing appearance of skin aging; and (iii) reducing or preventing acne.
NPR: "Recent fights between anti-abortion groups could leave people with the impression that the new health overhaul law expands women's access to abortion. But abortion-rights groups vehemently disagree."
Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat chronic and acute wounds, today launched Microcyn Skin & Wound HydroGel for both the U.S. professional and over-the-counter markets. The Microcyn HydroGel received FDA 510(k) marketing clearance in May of this year.
› Verified 8 days ago
| Entity Name | Kidney Specialists, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124038963 PECOS PAC ID: 7719871474 Enrollment ID: O20040212000294 |
News Archive
Gensignia scientific co-founders' research has been recognized in Clinical Cancer Advances 2015: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology published online in the Journal of Clinical Oncology (JCO) on January 20, 2015.
While several COVID-19 vaccines have been approved to date, the constant evolution of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) receptor-binding domain (RBD) has challenged the efficacy of these vaccines.
Palomar Medical Technologies Inc., a leading researcher and developer of light-based systems for cosmetic treatments, today announced the termination of its agreement with Johnson & Johnson Consumer Companies Inc ("JJCC"), a Johnson & Johnson company, to develop, clinically test and commercialize home-use, light-based devices for (i) reducing or reshaping body fat including cellulite; (ii) reducing appearance of skin aging; and (iii) reducing or preventing acne.
NPR: "Recent fights between anti-abortion groups could leave people with the impression that the new health overhaul law expands women's access to abortion. But abortion-rights groups vehemently disagree."
Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat chronic and acute wounds, today launched Microcyn Skin & Wound HydroGel for both the U.S. professional and over-the-counter markets. The Microcyn HydroGel received FDA 510(k) marketing clearance in May of this year.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr William A Wilmer, MD 595 Copeland Mill Rd, Suite 2d, Westerville, OH 43081-8908 Ph: (614) 823-8500 | Dr William A Wilmer, MD 595 Copeland Mill Rd, Suite 2d, Westerville, OH 43081-8908 Ph: (614) 823-8500 |
News Archive
Gensignia scientific co-founders' research has been recognized in Clinical Cancer Advances 2015: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology published online in the Journal of Clinical Oncology (JCO) on January 20, 2015.
While several COVID-19 vaccines have been approved to date, the constant evolution of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) receptor-binding domain (RBD) has challenged the efficacy of these vaccines.
Palomar Medical Technologies Inc., a leading researcher and developer of light-based systems for cosmetic treatments, today announced the termination of its agreement with Johnson & Johnson Consumer Companies Inc ("JJCC"), a Johnson & Johnson company, to develop, clinically test and commercialize home-use, light-based devices for (i) reducing or reshaping body fat including cellulite; (ii) reducing appearance of skin aging; and (iii) reducing or preventing acne.
NPR: "Recent fights between anti-abortion groups could leave people with the impression that the new health overhaul law expands women's access to abortion. But abortion-rights groups vehemently disagree."
Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat chronic and acute wounds, today launched Microcyn Skin & Wound HydroGel for both the U.S. professional and over-the-counter markets. The Microcyn HydroGel received FDA 510(k) marketing clearance in May of this year.
› Verified 8 days ago
Leah Wangeci Muthuri, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 625 Africa Rd Ste 240, Westerville, OH 43082 Phone: 614-508-2672 Fax: 614-508-2668 | |
Dr. John Joseph Ward, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 430 Altair Pkwy Ste 110, Westerville, OH 43082 Phone: 614-754-5500 Fax: 614-754-5501 | |
Nami L Cho, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 555 W Schrock Rd, Suite 110, Westerville, OH 43081 Phone: 614-882-0708 Fax: 614-882-2878 | |
Scott W Johnson, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 655 Africa Rd, Westerville, OH 43082 Phone: 614-326-2672 | |
Dr. David Brian Mcclure, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 300 Polaris Pkwy, Ste 3400, Westerville, OH 43082 Phone: 614-533-3475 Fax: 614-533-3480 | |
John B Krupko, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 625 Africa Rd Ste 200, Westerville, OH 43082 Phone: 614-891-8080 Fax: 614-891-7078 | |
Michael J Dial, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 6100 N Hamilton Rd, Westerville, OH 43081 Phone: 614-814-8490 Fax: 614-814-8520 |